331 related articles for article (PubMed ID: 22388626)
1. ¹¹¹In-DTPA⁰-octreotide (Octreoscan), ¹³¹I-MIBG and other agents for radionuclide therapy of NETs.
Bomanji JB; Papathanasiou ND
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S113-25. PubMed ID: 22388626
[TBL] [Abstract][Full Text] [Related]
2. Specific binding and uptake of 131I-MIBG and 111In-octreotide in metastatic paraganglioma--tools for choice of radionuclide therapy.
Spetz J; Dalmo J; Nilsson O; Wängberg B; Ahlman H; Forssell-Aronsson E
Horm Metab Res; 2012 May; 44(5):400-4. PubMed ID: 22566195
[TBL] [Abstract][Full Text] [Related]
3. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Madsen MT; Bushnell DL; Juweid ME; Menda Y; O'Dorisio MS; O'Dorisio T; Besse IM
J Nucl Med; 2006 Apr; 47(4):660-7. PubMed ID: 16595501
[TBL] [Abstract][Full Text] [Related]
4. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.
Gao Z; Biersack HJ; Ezziddin S; Logvinski T; An R
J Cancer Res Clin Oncol; 2004 Nov; 130(11):649-56. PubMed ID: 15300425
[TBL] [Abstract][Full Text] [Related]
5. The palliative role of 131I-MIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms.
Pasieka JL; McEwan AJ; Rorstad O
Surgery; 2004 Dec; 136(6):1218-26. PubMed ID: 15657579
[TBL] [Abstract][Full Text] [Related]
6. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Kaltsas GA; Papadogias D; Makras P; Grossman AB
Endocr Relat Cancer; 2005 Dec; 12(4):683-99. PubMed ID: 16322317
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB
AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455
[No Abstract] [Full Text] [Related]
10. Radiopharmaceuticals used for diagnosis and therapy of NETs.
Papachristou M
Hell J Nucl Med; 2023; 26 Suppl():19-20. PubMed ID: 37658556
[TBL] [Abstract][Full Text] [Related]
11. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
12. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
13. 131I-MIBG therapy of neural crest tumours (review).
Troncone L; Rufini V
Anticancer Res; 1997; 17(3B):1823-31. PubMed ID: 9179240
[TBL] [Abstract][Full Text] [Related]
14. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
15. Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide.
Barone R; Walrand S; Konijnenberg M; Valkema R; Kvols LK; Krenning EP; Pauwels S; Jamar F
Nucl Med Commun; 2008 Mar; 29(3):283-90. PubMed ID: 18349800
[TBL] [Abstract][Full Text] [Related]
16. Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults.
Postema EJ; McEwan AJ
Cancer Biother Radiopharm; 2009 Oct; 24(5):519-25. PubMed ID: 19877881
[TBL] [Abstract][Full Text] [Related]
17. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
18. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
[TBL] [Abstract][Full Text] [Related]
19. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
[TBL] [Abstract][Full Text] [Related]
20. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
